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1. Introduction
  Malaria is endemic in Nigeria with stable transmission over 
the year. The spread of HIV is also high within this area. 
Various studies in Nigeria have shown that there is a high 
prevalence of malaria among HIV infected individuals[1,2]. 
In a population based cohort, HIV infected individuals had 
significantly higher risk of having malaria parasitemia and 
developing clinical malaria than HIV negative individuals[3]. 
Oxidative stress has emerged in recent years as a suspected 
component in the pathogenesis of HIV disease. Increasing 
number of researchers agree that even in the earliest stages 
of infection, a deleterious reductive-oxidative (redox) 
imbalance may occurr[4]. During infections, neutrophils 
liberate free radicals and highly reactive oxidants both 
intracellularly and extracellularly in their attempt to destroy 
pathogens in the process termed respiratory burst[5]. The 
oxidants released include superoxide anion (O2), hydrogen 
peroxide (H2O2), singlet oxygen (O2
.
) and hydroxyl radicals 
(OH
-
). The respiratory burst consumes reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) which must be 
continuously restored if respiratory burst is to be mopped-
up. Restoration of NADPH is accomplished by way of 
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hexose monophosphate (HMP) pathway, by various rate 
limiting antioxidant enzyme mechanisms. These antioxidant 
enzymes include: glutathione peroxidase, glutathione 
reductase, superoxide dismutase, catalase, G-6-PD[6]. 
Defficiency of any of these enzymes can cause oxidative 
stress because NADPH is not replenished. Oxidative stress, 
viral replication and destruction of CD4+ T cells leads to 
progression of disease[7]. Furthermore it has been suggested 
that generation of reactive oxygen species (ROS) and 
associated oxidative stress play central role in development 
of systemic complications in malaria. This is because 
glutathione enzyme system, which includes glutathione 
peroxidase, glutathione S-transferase, and glutathione 
reductase are important antioxidants enzyme activity present 
in erythrocytes[8]. Therefore the present study was designed 
to evaluate the impact of HIV and malaria co-infection 
on antioxidant status of infected individuals in the South-
eastern Nigeria.
2. Materials and methods
  193 participants aged (39依18) years were recruited at the 
Voluntary Counselling and Testing unit of Nnamdi Azikiwe 
University Teaching Hospital Nnewi, Nigeria. 
  These participants were screened for HIV and Plasmodium 
falciparum (P. falciparum) infections, and grouped into: 
(i) asymptomatic HIV and malaria co-infected participants 
(n=39), (ii) asymptomatic HIV participants without 
malaria (n=35), (iii) symptomatic HIV and malaria co-
infected participants (n=35), (iv) symptomatic HIV infected 
participants without malaria (n=25), (v) HIV seronegative 
control participants with malaria (n=29) and (vi) HIV 
seronegative control participants without malaria (n=30). 
Blood samples collected from the participants were used 
for HIV screening, P. falciparum antigen screening, malaria 
parasite density, CD4+ T cell count, glutathione reductase, 
glutathione peroxidase and total antioxidant status. Standard 
laboratory methods were used for the analysis. Participants 
were staged using World Health Organisation guideline 
for HIV staging. Only those participants in HIV stage-
1(asymptomatic HIV infected) and stage- 2(symptomatic 
HIV infected) participated in the study. The HIV infected 
participants were not on any anti- retroviral therapy.
  Informed consent was obtained from those who participated 
in the study, while the ethical committee of Nnamdi Azikiwe 
University Teaching Hospital Nnewi approved the study 
design.
2.1. Sample collection
  Blood sample (6 mL )was collected from the participants 
and aliquoted into lithium heparin, plain and EDTA tubes 
for the determination of glutathione peroxidase activity; total 
antioxidant status and glutathione reductase activity; HIV 
seroreactivity, CD4+ T-cell count,  malaria parasite count 
and malaria parasite antigen detection respectively. 
2 .2 .  HIV  s c r een ings  by  bo th  immunoas say  and 
immunochromatographic methods
2.2.1. Immunoassay method
  HIV screening was performed using Abbot determine TM 
HIV-1 & 2 kit. (Abbot Japan Co ltd. Tokyo, Japan). The 
procedure was as described by the manufacturer. Briefly, 
50 毺L of plasma sample from participants were applied 
to appropriately labelled sample pads. After 15 minutes 
of sample application, the results were read. The inherent 
quality control of the kit validates the results. Two visible 
red lines occurs in the region labelled control and test 
represents HIV seropositive reaction while a single red 
colour in the region of control validates the test kit. Absence 
of red line in the test region represents HIV seronegative 
reaction.
2.2.2. Immunochromatographic method
  HIV screening by immunochromatographic method using 
HIV 1 and 2 STAT-PAK Assay kit; for the qualitative 
detection of antibodies to HIV-1 and HIV-2 in human 
plasma (Chembio diagnostic system, INC. New York, USA). 
The procedure was as described by the manufacturer 
of the kit. 50 毺L of plasma sample was dispensed into 
appropriately labelled sample wells, and then three drops 
of running buffer (supplied by the manufacturer) was added 
drop-wise into the appropriately labelled sample wells. The 
results of the test were read at 10 minutes after the addition 
of the running buffer. 
2.3. P. falciparum antigen detection 
  The procedure was as described by the manufacturer (Para 
check, Orchid Biomedical systems Vena Goa, India). Briefly, 
10 毺L of the whole blood specimen from the participants 
were transferred into appropriately labelled specimen 
cassettes containing sample wells. Subsequently, 120 毺L 
of clearing buffer was added into the sample wells. After 15 
minutes, the results were read.
2.4. Determination of P. falciparum parasite density
  Giemsa Stained Thick and thin blood smear for microscopic 
detection of P. falciparium parasites was made. Thin and 
thick blood films were prepared for each participant and 
allowed to dry. After drying, the films were examined using 
the 伊100 oil immersion objective. The parasite density 
was determined by recording the number of malaria 
parasite detected within a high powered field count of 
200 white blood cells (WBC). This was then multiplied by 
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the participants total white blood cell count (TWBC).  The 
number of parasite per 毺L of blood was calculated. The 
procedure was repeated in two other areas of the field and an 
average of the three counts was taken, and malaria parasite 
density was calculated as follows: 
Parasite count = TWBC count 伊 number of parasites counted 
within 200 WBC/200. 
2.5. Determination of CD4 + T cell count
  50 毺L of whole blood in EDTA anti-coagulant was 
dispensed into a partec test tube and 10毺L of CD4 PE 
antibody was added. The reaction mixture was incubated 
in the dark for 10-15 minutes. After incubation, 800 毺L 
of the already prepared diluted buffer (Xn 0.09% NaN3) was 
added to each reaction tube and vortexed. The partec tubes 
containing these reactions were plugged in position in the 
Cyflow SL Green (Partec Germany), which has already been 
connected to flow max software, CD4 count template data file 
and CD4 count instrument. The test was run on the Cyflow 
for 90 seconds. The results were displayed as histogram and 
printed. The CD4+ T-Cell count was read off the histogram 
correcting for the dilution factor.
2.6. Determination of glutathione peroxidase enzyme
  The procedure was as described by the manufacturer of 
the kit (Randox Laboratories Ltd, UK). In brief, 0.05 mL of 
heparinized whole blood from each of the participant was 
dispenced in appropriately labelled test tubes containing
1 mL of diluting agent (0.18 mmol/L). This was incubated 
for 5 minutes. After the incubation, 1 mL of haemoglobin 
reagent (containing I volume of haemoglobin reagent with 
4 volumes redistilled water) was added. This was mixed 
very well and assayed within 20 minutes for glutathione 
peroxidase as follows: 0.02 mL of the diluted sample was 
added in a labelled separate test tubes containing 1 mL of 
Reagent 1 [Glutathione 4 mmol/L, glutathione reductase 
0.5U/L and NADPH 0.34 mmol/L in phosphate buffer PH 7.2 
(0.05 mol/L, and EDTA, 4.3 mmol/L)], and 0.04 mL of Cumene 
solution (Cumene hydroxide, 0.18 mmol/L). The reagent 
blank was prepared similarly with 0.02 mL of distilled 
water in place of the sample. This was mixed gently and 
the absorbance of sample and reagent blank was read at 
340 nm against air after 1, 2 and 3 minutes. The change in 
absorbance of both sample and reagent blank was calculated 
and the concentration of glutathione peroxidase calculated 
using a factor of 8 412 after subtracting the absorbance of 
blank from that of sample.
2.7. Determination of glutathione reductase enzyme
  The procedure was as described by the manufacturer of the 
kit (Randox Laboratories Ltd, UK). 40 毺L of serum from each 
of the participant was dispenced in appropriately labelled 
test tube containing 1 000 毺L of substrate (2.2 mmol/L
reduced glutathione in 5 mL of 250 mmol/L potassium 
phosphate buffer, PH 7.3 and 5 mmo/L EDTA) and 200 毺L
NADPH (0.17 mmol/L). This was mixed and the initial 
absorbance was read after 1 minute at 340 nm against air. 
This was read again after 2, 3, 4, and 5 minutes. The average 
change in absorbance was calculated and used to calculate 
the glutathione reductase activity in U/L by multiplying by a 
factor of 4 983.
2.8. Determination of total antioxidant status
  This was as described by the manufacturer of the kit 
(Randox Laboratories Ltd, UK). 20 毺L of serum was added 
into a test tube containing 1 000 毺L of 2,2’-Azino-di-(3-
ethylbenzthiazoline sulphonate), and 1 000 毺L of chromogen 
(6.1 毺mol/L of metmyoglobin in 10 mL of 80 mmol/L
phosphate buffered saline (PH 7.4). Standard and 
reagent blank were prepared in the same way using 
a standard solution containing (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid) and double distilled 
water respectively. 25 毺L hydrogen peroxide was added 
to all tubes and mixed. The absorbance was read after 
3 minutes at 660 nm against air at 37 曟. The change in 
absorbance of sample and blank was calculated and used to 
determine the total antioxidant status.
2.9. Statistical analysis
  The variable were expressed in mean and standard 
deviation. ANOVA and Student-t test were used to check 
for significant differences in variables amongst and within 
the groups. Significant level were considered at P<0.05 and 
P<0.01.
3. Results
  Table 1 shows significant differences in serum activities of 
glutathione reductase (U/L), glutathione peroxidase (U/gHb) 
and total antioxidant status (mmol/L) in asymptomatic HIV 
infected participants with and without malaria and in control 
participants with and without malaria co-infection (P<0.01). 
Group comparison shows that the antioxidants measured 
were significantly lower in asymptomatic HIV infected 
participants with and without malaria co-infection and in 
control participants with malaria compared with control 
participants without malaria (P<0.05) in each case (Table 1). 
The CD4+ T cell count were also significantly lowered in both 
asymptomatic HIV infected participants with and without 
malaria compared with control participants (P<0.05) in each 
case.
  Table 2 shows significant differences observed in mean 
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serum activity of glutathione reductase (U/L), glutathione 
peroxidase (U/gHb) and total antioxidant status (mmol/L) in 
symptomatic HIV infected participants with and without 
malaria co-infections and in control participants with and 
without malaria co-infection (P<0.01). Group comparison 
shows that the antioxidants measured were significantly 
lower in symptomatic HIV infected participants with and 
without malaria co-infection and in control participants with 
malaria compared with control participants without malaria 
(P<0.01) in each case. 
  Table 3 and Figure 1 shows that in asymptomatic HIV 
participants with malaria co-infection there was significant 
correlation between CD4+ T cell count and glutathione 
reductase (r=0.953, P<0.01) and between CD4+ T cell count 
and glutathione peroxidase (r=0.711, P<0.01).  There was also 
a significant negative correlation between malaria parasite 
density and glutathione reductase (r = -0.492, P<0.05) and 
between malaria parasite density and glutathione peroxidase 
(r= -0.584, P<0.05) in asymptomatic HIV participants with 
malaria co-infection. 
  In Table 3 and Figure 2&3, a strong significant negative 
correlation was observed between malaria parasite density 
and the antioxidants glutathione reductase (r=-0.906, 
P<0.01), glutathione peroxidase (r=-0.719, P<0.01) and 
total antioxidant status (r=-0.824, P<0.01) in symptomatic 
HIV participants with malaria co-infection.  Also a positive 
relationship was observed between CD4+ T cell count 
and glutathione reductase (r=0.827, P<0.01), glutathione 
peroxidase (r=0.864, P<0.01) (Figure 2) and total antioxidant 
status (r=0.833, P<0.01) (Figure 3) in symptomatic HIV 
Table 1
Serum/plasma activities of antioxidants, CD4+ T cells and P. falciparum density in asymptomatic HIV infected and HIV seronegative control 
participants with or without malaria (Mean依SD). 
Group  Glutathionereductase
 (U/L) 
Glutathione peroxidase
 (U/gHb)     
Total antioxidan
 (mmol/L)   
CD4 T cell count 
  (/毺L)  
P. falciparum density 
(/毺L)  of blood   
Asymp HIVwith malaria a (n=39) 55.87依5.25 49.63依5.97   1.43依0.09 416.08依204.38   831.62依231.12
Asymp HIV without malaria b (n=35) 59.46依6.05 49.49依6.35 1.45依0.08 395.73依156.65    -
Control with malaria c (n=29) 54.79依3.47 52.56依1.95   1.54依0.07*$    950.00依142.58*☆    463.80依132.44*
Control Without malaria d (n=30)      68.77依5.96*$△      66.58依2.71*$△       1.60依0.07#☆△  1012.92依190.90#☆ -
F (P) value 6.633e 6.814e 4.178f 12.366f nc
F(P) = asymptomatic HIV with or without malaria and HIV seronegative control with or without malaria compared (using ANOVA), e= P<0.05, 
f=P<0.01, nc = not compared; a = Asymp HIV with malaria, b= Asymp HIV without malaria, c = Control with malaria; Group comparison was 
analyzed with student t test, Symp = symptomatic; *P<0.05 comparing with a; # P<0.01 comparing with a; $ P<0.05 comparing with b; R: P<0.01 
comparing with b; △P<0.01 comparing with c.
Table 2 
Serum/plasma activities of the antioxidants and P. falciparum density in symptomatic HIV infected and HIV seronegative control participants 
with or without malaria (Mean依SD). 
Group Glutathione reductase
 (U/L)
Glutathione peroxidase
 (U/gHb) 
Total Antioxidant
 (mmol/L)
CD4 T Cell  count 
(/毺L)  
P. falciparum density 
of blood (/毺L)
Symp HIVwith malaria a (n=35) 43.93依6.27  42.95依4.57 1.39依0.06  171.56依49.04 1254.24依478.92 
Symp HIV without
malaria b  (n=25)
 49.03依6.05* 7.32依4.35* 1.41依0.04 155.27依44.00 -
Control  with malaria c  (n=29)  54.79依3.47# 2.56依1.95#    1.54依0.07#☆       950.00依142.58#☆  463.80依132.44#
Control Without malaria d (n=30)       68.77依5.96#☆△    66.58依2.71#☆△      1.60依0.07#☆△       1012.92依190.90#☆△ -
F (P) Value 8.229f 9.920f 8.426f  15.341f nc
F(P) = asymptomatic HIV with or without malaria and HIV seronegative control with or without malaria compared (using ANOVA), f=P<0.01 nc 
= not compared; a = Asymp HIV with malaria, b= Asymp HIV without malaria, c = Control with malaria; Group comparison was analyzed with 
student t test, Symp = symptomatic; *P<0.05 comparing with a; # P<0.01 comparing with a; $ P<0.05 comparing with b; R: P<0.01 comparing 
with b; △P<0.01 comparing with c.
Table 3
Correlation between malaria parasite density, antioxidants and CD4 T cell counts in asymptomatic HIV infected participants with or without 
malaria. 
Participants
Asymptomatic HIV participants Symptomatic HIV participants Control HIV participants
GR cell GP TAS
MP
 ensity
CD4 GR cell GP TAS
MP
 density
CD4 GR cell GP TAS
MP
density
CD4
Participants
with malaria
MP Density -0.492b -0.584b -0.157 1.0 - -0.906c -0.719c -0.824c 1.0 - -0.50b -0.663b 0.124 1.0 -
CD4 T cell
 count
0.953c 0.711 c 0.572b - 1.0 0.827c  0.864 c 0.833 c - 1.0 0.312 0.164 0.040 - 1.0  
Participants
without malaria
CD4 T cell
 count
0.533 b 0.326 b 0.477 b - 1.0 0.855 c 0.716 c 0.812 c -  1.0 0.147  0.157 0.086 - 1.0  
Correlation were analyzed by Pearson's correlation, b = correlation significance at P<0.05, c = Correlation significance at P<0.01.
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participants with malaria co-infection. 
  There was no significant correlation observed between 
CD4
+ T cell count and the antioxidants in HIV seronegative 
control participants with or without malaria but there 
was a significant correlation between malaria parasite 
density and glutathione reductase (r=-0.50, P<0.05) and 
glutathione peroxidase (r=-0.663, P<0.01) respectively in 
HIV seronegative control participants with malaria (Table 3 
and Figure 4-6).
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Figure 1. Scatter plot between CD4 T cell count and glutathione 
reductase in Asymptomatic HIV infected participants with malaria.
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Figure 2. Scatter plot between CD4 T cell count and glutathione 
peroxidase in symptomatic HIV infected participants with malaria.
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Figure 3. Scatter plot between CD4 T cell count and total antioxidant 
status in symptomatic HIV infected participants with malaria.
600.00
550.00
500.00
450.00
400.00
350.00
300.00
x=-486.99+598.92y, R2=0.124
  1.45                   1.50                   1.55                   1.60                    1.65
Total antioxidant status(mmol/L)
M
al
ar
ia
 p
ar
as
it
e 
de
ns
it
y(
/ 毺
L
 o
f b
lo
od
)
Figure 4. Scatter plot between malaria parasite density and total 
antioxidant status in HIV seronegative control participants with 
malaria.
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Figure 5. Scatter plot between CD4 T cell count and glutathione 
reductase in HIV seronegative control participants without malaria.
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Figure 6. Scatter plot between CD4 T cell count and glutathione 
reductase in HIV seronegative control participants with malaria.
4. Discussion
  This study examined the antioxidant activity of 
asymptomatic and symptomatic HIV infected participants 
with or without malaria co-infection. The present study 
showed that the concentrations of glutathione peroxidase, 
glutathione reductase, and serum levels of total antioxidant 
status were significantly lowered in asymptomatic and 
symptomatic HIV seropositive participants with or without 
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malaria co-infection compared with control participants. 
This reduction increases as the HIV disease progresses 
as observed from the study; symptomatic HIV infected 
participants having lower level of these antioxidants 
compared with asymptomatic HIV infected participants. 
The lowered antioxidant level may compromise the ability 
of HIV infected individuals to scavenge free radicals 
and oxygen reactive species, which might predispose 
them to disease progression. Progression of disease have 
been associated with conditions that predisposes to high 
production of free radical and oxygen reactive species and 
those that predisposes to depletion of antioxidants. In people 
living with HIV and AIDS, decreased levels of antioxidants 
and increased oxidative stress have been documented [9-11].
The compromised status of glutathione reductase, 
glutathione persoxidase and TAS could be attributed to 
greater utilization of antioxidant micronutrients subsequent 
to increased oxidative stress, and/or inadequate availability 
of carrier molecules that may influence circulation of 
antioxidant concentrations[12]. 
  Our results clearly show that severe antioxidant depletion 
occurs in HIV seropositive individuals in comparison 
with controls and with the progression of disease. This is 
confirmed with the finding of a strong correlation between 
CD4
+ T cell count and the antioxidants. The lower the CD4+ 
T cells count the lower the antioxidants.  This assertion is 
considered valid considering the role of antioxidants in 
normal immune function. Exposure to oxidants challenges 
cellular systems and their responses may create conditions 
that are favourable for the replication of viruses in HIV and 
decrease in CD4+ T cells. As oxidative stress increases so 
does viral replication which increases the destruction of 
CD4
+ T cells and progression of disease [7]. Since the immune 
system is constantly stimulated in HIV infection and 
antioxidant level is lower in HIV seropositive individuals 
than in control participants as observed from the study, 
adequate intake of antioxidants and phytochemcals is 
critical in minimizing oxidative stress. The significantly 
lower concentration of antioxidants among symptomatic 
HIV infected participants than asymptomatic HIV infected 
participants suggests that these antioxidants may be utilized 
in the face of increased viral load.
  The low activity of glutathione reductase and glutathione 
peroxidase may be influenced by the intake of nutrients 
required for enzyme activity; one example is selenium which 
is strongly required for glutathione peroxidase activity. 
Selenium a crucial component of glutathione peroxidase is 
important in the progression of HIV disease because it is 
involved in gene regulation and viral expression. The HIV 
virus replicates more slowly with adequate selenium and 
selenium rich glutathione peroxidase than when selenium 
and glutathione peroxidase is deficient. Viral load affect 
the progression of HIV disease. HIV infected individuals 
experience chronic immune stimulation from fighting 
the virus with a corresponding increase in free radical 
production and a decrease in antioxidant nutrients and 
antioxidant enzymes. This results in oxidative stress which 
causes an increase in the production of HIV virus and 
promotes cell death particularly of CD4+ T lymphocytes[13, 14].
  Further analysis of our finding show that glutathione 
reductase and glutathione peroxidase were significantly 
lower in asymptomatic and symptomatic HIV infected 
participants with malaria compared with control participants 
with or without malaria. This means that malaria exerted 
a great burden on the antioxidant activity. Even between 
the control participants, those with malaria presented 
with lowered antioxidant activity. Hence malaria infection 
seem to present with a higher demand on antixidant. 
Glutathione reductase and glutathione peroxidase deficient 
erythrocytes serve as host cells for malaria parasites[15] and 
they are among the important antioxidant enzyme present 
in the erythrocytes. Evidence has been shown that HIV 
seropositive individuals and those infected with malaria 
suffer from oxidant/antioxidant imbalance[3,12]. There 
was a significant negative correlation between malaria 
parasite density compared with glutathione reductase and 
glutathione peroxidase. This pattern of antioxidant status is 
a reflection of the malaria pathogenesis, which involves the 
invasion of human erythrocytes by the malaria parasite. This 
brings about metabolic changes in the host cell. The host 
cells may then become vulnerable to damage due to toxic 
metabolites derived from both host and parasites. Reactive 
oxygen species generated in the host-parasite interaction 
cause lysis of erythrocytes and alteration of the antioxidant 
enzymes. This has been documented by[16,17].
  In HIV and malaria co-infection there may likely be 
greater generation of reactive oxygen species and resultant 
depletion of antioxidants as they scavenge the surge in 
the latter. Since the lowered activity of the antioxidant 
enzymes and total antioxidant status are much pronounced 
in symptomatic HIV than asymptomatic HIV it is a possible 
indication that reduction of antioxidants in HIV seropositive 
individuals increases as the disease progresses. This shows 
that as HIV infection progresses there may be greater 
demand for antioxidants. This finding is further skewed 
in cases of malaria co-infection in HIV participants. 
This calls for greater concern in malaria endemic area 
where incidences of HIV- malaria co-infection has been 
reported[1,2].
  Malaria infection may accelerate the degree of reduction 
of glutathione reductase, and glutathione peroxidase in HIV 
positive individuals as the present study have shown. Thus 
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malaria infection depletes the erythrocytes of its defence 
against oxidative stress due to the reduced activities of 
glutathione reductase and glutathione peroxidase. 
  The study showed significant increase in malaria parasite 
density and a decrease in CD4+ T cell count in symptomatic 
HIV infected participants with malaria compared to 
asymptomatic HIV infected participants with malaria. This 
shows that the incidence of clinical malaria may increase 
with decreasing CD4+ T cell count.  HIV weakens the body’s 
immune response to malaria and malaria has been shown to 
induce HIV-1 replication and increase HIV viral load[18-22]. 
Various studies in Nigeria have shown that there is a high 
prevalence of malaria among HIV infected individuals[1,2,19]. 
This means that the impact of the interaction of malaria and 
HIV/AIDS will be most apparent in areas with generalized 
HIV/AIDS epidemic and malaria endemic areas such 
as Nigeria. Therefore strategies to reduce the burden of 
malaria morbidity and mortality especially in those infected 
with HIV must be re-enforced. Antioxidant treatment in 
combination with antimalaria may be a successful strategy 
for HIV infected individuals residing in malaria endemic 
areas.
Conflict of interest statement
  We declare that we have no conflict of interest.
References
[1]   Uneke CJ, Ogba O, Inyama PU, Anyanwu GL. Malaria infection in 
HIV seropositive & HIV seronegative individuals in Jos Nigeria. 
MEJSR 2005; 5: 18-33.
[2]   Onyenekwe CC, Ukaibe N, Meludu SC, Ilika A, Aboh N, Ofiaeli 
N, et al. Prevalence of malaria as co-infection in HIV infected 
individuals in a malaria endemic area of South Eastern Nigeria. J 
Vector Borne Dis 2007; 44: 250-254.
[3]   Audu RA, Onwujekwe DI, Onubogu CC, Adedoyin JA, Onyejepu 
N, Mafe AG, et al. Possible impact of co-infections of tuberculosis 
and malaria on the CD4+ cell counts of HIV patients  in Nigeria. 
Ann Afr Med 20005; 4(1): 10-13.
[4]   Ene A, Hary T, Gadzema A, Ajay B, Bitube B,  Bakbuk P. 
Biochemical abnormalities associated with HIV-1 infection as 
observed in Maiduguri, North-Eastern Nigeria. Res J Med  Med 
Sci 2006; 1: 82-84.
[5]   Madhavi M, Samudram P, Hemanth Kuman A, Lalitha V. Effect 
of antioxidants vitamin C and E supplementation and its plasma 
levels on lipid profile in pulmonary TB patients. Am J Infec Dis 
2009; 5(3): 263-272.
[6]   Schofield L, Gran G. Immunological process in malaria 
pathogenesis. Nat Rev Immunol 2005; 5: 722-735.
[7]   Cole S, Langkamp-Henken B, Bender B, Findley K, Herringer 
Garcia K, Uphold C. Oxidative stress and antioxidants capacity 
in smoking and non smoking men. Nutr Clin Pract 2005; 20 (6): 
662-667.
[8]   Mc Gilvray I, Serghides L,  Kapur O, Rostein O, Kan K. Non-
opsonic monocyte/macrophage phargocytosis of Plasmodium 
falciparum-parasitized erythrocytes: A role for CD 36 in malarial 
clearance. Blood  2000; 96: 3231-3240.
[9]   Sundarama M, Saqhayama S, Priyaa B, Venkateshp K, 
Balakrishana P, shankara E, et al. Changes in antioxidant profile 
among HIV infected individuals on generic HAART therapy in 
Southern India. IJID 2008; 12(6): 61-66.
[10] Das B, Patnaik J, Mohanty S, Mishra S, Mohanty D, Satpathy 
S, et al. Plasma antioxidants and lipid peroxidation products in 
falciparum malaria. Am J Trop Med Hyg 1993; 49(6): 720-725.
[11] Durgesh N, Vyas R, Sharma M, Yogita S, Raynee S. Comparison 
in serum profile of peroxidants and non-enzymatic antioxidants 
among patients suffering from malaria. JPMI 2011; 25 (2): 96-
100.
[12] Olaniyi J, Arinola O. Essential trace elements and antioxidant 
status in relation to severity of HIV in Nigeria patients. Med Princ 
Pract 2007; 16(6): 420-425.
[13] Kolter DP. The biology of human immunodeficiency virus 
infection. Nutr Clin Prac 2004; 19: 324-329.
[14] Ogunro P, Ogungbamigbe T, Elemie P, Egbewale B, Adewole T. 
Plasma selenium concentration and glutathione peroxidase activity 
in HIV/AIDS infected patients: a correlation with the disease 
progression. Niger Postrad Med J 2006; 13(1): 1-5.
[15] Zhang M, Gong J, Iyer OV, Jones BE, Modlin RL, Barnes PF.  T 
cell cytokine response in persons with tuberculosis and human 
immuniodeficiency virus infection J Clin Invest 1994; 14: 2435-
2442.
[16] Nmorsi O, Ukwandu N, Egwunyenga A. Antioxidant status of 
Nigerian children with P. falciparum malaria. AJMR 2007; 1(5): 
61-64.
[17] Erel K, Avei S, Aktepe N, Bulut V. Oxidative stress and 
antioxidant status of plasma and erythrocytes in patients with 
vivax malaria. Clin Biochem 1997; 30: 631-639.
[18] Abu-Raddad L, Patnaik P, Kublim J. Dual infection in HIV and 
malaria fuels the spread of both diseases in sub Saharan African. 
Science 2006; 314: 1603-1606.
[19] Onifade AK, Akanni EO, Mewoyeka OO. Incidence of malaria 
infection among HIV patients in Ondo State Nigeria. MEJSR 
2007; 2: 48-53.
[20]  Prasad SK, Kumar R, Patel DK, Sahu AN, Hemalatha S. 
Physicochemical standardization and evaluation of in-vitro 
antioxidant activity of Aconitum heterophyllum Wall. Asian Pac J 
Trop Biomed 2012; 2(Suppl 2): S526-S531.
[21]  Narender PD, Rao BG, Rao ES, Rao T, Praneeth VSD. 
Quantification of phytochemical constituents and in-vitro 
antioxidant activity of Mesua ferrea leaves. Asian Pac J Trop 
Biomed 2012; 2(Suppl 2): S539-S542.
[22]  Osahon AI, Ukponmwan CU, Uhunmwangho OM. Prevalence of 
HIV seropositivity among patients with squamous cell carcinoma 
of the conjunctiva. Asian Pac J Trop Biomed 2012; 2(Suppl 2): 
150-153.
